{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:33Z","timestamp":1792013913342,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171800"],"award-info":[{"award-number":["82171800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022-PUMCH-C-103"],"award-info":[{"award-number":["2022-PUMCH-C-103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022-PUMCH-A-105"],"award-info":[{"award-number":["2022-PUMCH-A-105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clim.2023.109298","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T13:10:33Z","timestamp":1679663433000},"page":"109298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Baricitinib for the treatment of refractory vascular Beh\u00e7et's disease"],"prefix":"10.1016","volume":"250","author":[{"given":"Zhimian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clim.2023.109298_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Beh\u00e7et syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2023.109298_bb0010","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clim.2023.109298_bb0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14712598.2017.1328496","article-title":"Management of severe complications in Beh\u00e7et\u2019s disease with TNF inhibitors","volume":"17","author":"Desbois","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"11","key":"10.1016\/j.clim.2023.109298_bb0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2023.109298_bb0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"International team for the revision of the international criteria for Behcet's D. the international criteria for Behcet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.clim.2023.109298_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","article-title":"Long-term outcome of arterial lesions in Beh\u00e7et disease","volume":"91","author":"Saadoun","year":"2012","journal-title":"Medicine."},{"key":"10.1016\/j.clim.2023.109298_bb0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109298_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.635663","article-title":"Contribution of Janus-kinase\/signal transduction activator of transcription pathway in the pathogenesis of Vasculitis: a possible treatment target in the upcoming future","volume":"12","author":"Bursi","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.clim.2023.109298_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"issue":"1","key":"10.1016\/j.clim.2023.109298_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2023.109298_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.clim.2023.109298_bb0060","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","article-title":"Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study","volume":"80","author":"Liu","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.clim.2023.109298_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clim.2023.109298_bb0070","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2019-216900","article-title":"Targeting JAK\/STAT pathway in Takayasu\u2019s arteritis","volume":"79","author":"R\u00e9gnier","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2023.109298_bb0075","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of Behcet\u2019s disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2023.109298_bb0080","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et\u2019s disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.clim.2023.109298_bb0085","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.intimp.2013.07.017","article-title":"Possible mechanisms of neutrophil activation in Beh\u00e7et\u2019s disease","volume":"17","author":"Neves","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.clim.2023.109298_bb0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2023.109298_bb0095","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clim.2023.109298_bb0100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf."},{"issue":"8","key":"10.1016\/j.clim.2023.109298_bb0105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2023.109298_bb0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2022","journal-title":"Ann. Rheum. Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:02:59Z","timestamp":1778616179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":22,"alternative-id":["S1521661623000773"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109298","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib for the treatment of refractory vascular Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109298"}}